Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions - PubMed

2 days ago

Pulmonary hypertension (PH) associated with left heart disease (LHD) is the most common form of PH, linked to high morbidity and mortality.
Diagnosis is difficult due to overlapping phenotypes, unreliable echocardiographic estimates, and dependence on invasive hemodynamic tests.
Current pulmonary arterial hypertension drugs show no benefit and may be harmful for PH-LHD patients.
No approved pharmacologic or interventional therapies exist specifically for PH-LHD, aside from treatments targeting the underlying LHD.
Emerging therapies under investigation include sotatercept, relaxin analogues, levosimendan, pulmonary artery denervation, transcatheter atrial shunts, and pericardiotomy.
Clinical trials face challenges such as patient recruitment, phenotypic variability, and lack of standardized outcomes.
The review outlines current knowledge, emerging treatments, trial design barriers, and future research directions for PH-LHD.

Hasty Briefsbeta